Literature DB >> 28602484

Red blood cell transfusion and outcome in cancer.

Nayyer Iqbal1, Kamal Haider1, Vinita Sundaram2, Julia Radosevic3, Thierry Burnouf4, Jerard Seghatchian5, Hadi Goubran6.   

Abstract

Oncology services utilize about 15% of the blood transfusion resources in the USA. Red blood cell transfusion is performed immediately before, during or after major surgery to compensate for blood loss and hemodilution. However, a lack of evidence-based guidelines leads to variable transfusion practices among clinicians. The benefits of transfusing blood products are obvious in life-threatening low blood cell counts or bleeding, but it is becoming apparent that deliberate blood transfusion in some cancer patients can trigger negative clinical impacts. This review attempts to provide an overview of the impact of red blood cell transfusion in patients suffering from various types of oncologic pathologies. Crown
Copyright © 2017. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Cancer; Prognosis; Recurrence; Red blood cells; Transfusion

Mesh:

Year:  2017        PMID: 28602484     DOI: 10.1016/j.transci.2017.05.014

Source DB:  PubMed          Journal:  Transfus Apher Sci        ISSN: 1473-0502            Impact factor:   1.764


  5 in total

1.  Responses of human colon and breast adenocarcinoma cell lines (LoVo, MCF7) and non-tumorigenic mammary epithelial cells (MCF-10A) to the acellular fraction of packed red blood cells in the presence and absence of cisplatin.

Authors:  Kamila Czubak-Prowizor; Anna Macieja; Tomasz Poplawski; Halina Malgorzata Zbikowska
Journal:  PLoS One       Date:  2022-07-08       Impact factor: 3.752

2.  Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study.

Authors:  Se Young Choi; Moon Soo Ha; Byung Hoon Chi; Jin Wook Kim; In Ho Chang; Tae-Hyoung Kim; Soon Chul Myung; Myoungsuk Kim; Kyung-Eun Lee; Yuwon Kim; Hyun-Ki Woo; Dae-Sung Kyoung; Hasung Kim
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-21       Impact factor: 4.322

3.  Packed Red Blood Cell Supernatants Do Not Promote Growth or Cisplatin Resistance of Myeloid Leukemia K-562 Cells.

Authors:  Kamila Czubak-Prowizor; Anna Macieja; Tomasz Poplawski; Halina Malgorzata Zbikowska
Journal:  J Blood Med       Date:  2022-03-05

4.  Effect of Perioperative Blood Transfusion on the Postoperative Prognosis of Ruptured Hepatocellular Carcinoma Patients With Different BCLC Stages: A Propensity Score Matching Analysis.

Authors:  Feng Xia; Qiao Zhang; Zhiyuan Huang; Elijah Ndhlovu; Mingyu Zhang; Xiaoping Chen; Bixiang Zhang; Peng Zhu
Journal:  Front Surg       Date:  2022-03-22

5.  Red blood cell transfusions impact response rates to immunotherapy in patients with solid malignant tumors.

Authors:  Rebekka Mispelbaum; Sandra Tessa Hattenhauer; Peter Brossart; Annkristin Heine
Journal:  Front Immunol       Date:  2022-09-08       Impact factor: 8.786

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.